---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Place in treatment, anticipated use, and care setting. Topics: Summary: target population, Summary: position relative to current first-line therapy, Summary: anticipated use and care setting, Target population named in the Breakthrough Therapy Designation, and 10 further topics. 14 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary: target population

The Breakthrough Therapy Designation covers ficerafusp alfa with pembrolizumab “for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death-ligand 1 with combined positive score (CPS) ≥1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.” The pivotal FORTIFI-HN01 trial (NCT06788990) enrolls recurrent or metastatic HNSCC with a primary tumor in the “oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC)”; paranasal sinus and nasopharyngeal primaries are excluded. The EU trial record requires “documentation of HPV-negative disease per central testing performed if presenting with OPSCC”, and lists the development of an HPV DNA assay among the sponsor's delegated duties. HPV status is therefore established by testing only for oropharyngeal primaries; Bicara states that HPV testing is “typically only being conducted in tumors originating from the oropharynx”, and the College of American Pathologists recommends against routine HR-HPV testing of primary oral cavity, laryngeal, nasopharyngeal, and hypopharyngeal carcinomas for prognostic purposes. Participants must have “PD-L1 CPS ≥1”, which the EU record specifies as “PD-L1 immunohistochemistry [IHC] via 22C3” in participants eligible “to receive pembrolizumab as frontline monotherapy”. Other criteria are no prior systemic therapy in the recurrent or metastatic setting, systemic therapy for locoregionally advanced disease completed more than 6 months earlier, no prior anti-EGFR antibody outside radiosensitizing or multimodal treatment, no immune checkpoint inhibitor within 6 months, measurable disease by RECIST 1.1, ECOG performance status 0 or 1, and no higher risk of bleeding.

Source: [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted); [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990); [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Faquin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12480157/)

<a id="topic-2.2.2.2-2"></a>

### Summary: position relative to current first-line therapy

Ficerafusp alfa would be added to pembrolizumab in first-line treatment, the setting in which pembrolizumab monotherapy (CPS ≥1) and pembrolizumab with platinum and fluorouracil are FDA approved, offered by ASCO with a strong recommendation for CPS ≥1, and listed by NCCN as preferred first-line options. The intended population overlaps the pembrolizumab monotherapy label population, which requires CPS ≥1 by an FDA-authorized test. Hanna et al. state that the combination “could provide a chemotherapy-free regimen”. Bicara reports a “two-to-three-fold increase in median OS” relative to pembrolizumab monotherapy or pembrolizumab with chemotherapy, and states that “No head-to-head studies have been conducted, and cross-trial comparisons may not be reliable”. The available results for ficerafusp alfa are from a single-arm phase 1b trial; topline results of the FORTIFI-HN01 interim analysis are expected in mid-2027, with a potential U.S. launch in 2028.

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328); [Pfister et al. (2020)](https://jnccn.org/view/journals/jnccn/18/7/article-p873.xml); [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Bicara Therapeutics third quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2026-financial-results); [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-2.2.2.2-3"></a>

### Summary: anticipated use and care setting

Bicara estimates about 50,000 HPV-negative patients newly diagnosed each year in the United States, EU5, and Japan, about 18,000 of them in the United States, and states that 80% of recurrent or metastatic HNSCC is HPV-negative. In KEYNOTE-048, 85% of tumors had CPS ≥1; among U.S. real-world first-line pembrolizumab recipients with a CPS result (352 participants, 54.5% of the cohort), 83.8% had CPS ≥1. In a U.S. nationwide database drawn primarily from community practices, 32.7% of 2,207 participants with recurrent or metastatic HNSCC received PD-L1 testing before first-line therapy and 50.0% were never tested. In the phase 1b trial, ficerafusp alfa 1,500 mg was given intravenously on days 1, 8, and 15 of 21-day cycles with pembrolizumab 200 mg on day 1; the protocol specifies a 120-minute infusion, extendable to 4 hours, and observation with vital-sign monitoring for 2 hours after the first 2 doses. Bicara is developing a less frequent dosing regimen. Among U.S. real-world first-line pembrolizumab recipients, 583 (90.2%) were treated in community practices and 57 (8.8%) in academic practices.

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/); [Hanna et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39754998/); [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [Bicara Therapeutics clinical trial protocol BCA101X1101 (2024)](https://ascopubs.org/doi/suppl/10.1200/JCO-25-02027/suppl_file/protocol_JCO-25-02027.pdf); [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.2.2.2-4"></a>

### Target population named in the Breakthrough Therapy Designation

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ficerafusp alfa in combination with pembrolizumab for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death-ligand 1 with combined positive score (CPS) ≥1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.”

Source: [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted)

<a id="topic-2.2.2.2-5"></a>

### Intended first-line use in combination with pembrolizumab

> “We are currently conducting a global, randomized, double-blind, Phase 2/3 FORTIFI-HN01 pivotal trial evaluating 1500mg dosed once weekly, or QW, of ficerafusp alfa in combination with pembrolizumab in first-line, or 1L, recurrent/metastatic, or R/M, human papillomavirus infection, or HPV, -negative head and neck squamous cell carcinoma, or HNSCC, whose tumors express programmed death-ligand 1 with combined positive score, or CPS, of ≥1.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.2.2.2-6"></a>

### Company estimate of the target population

| Population | Company estimate |
| --- | --- |
| HPV-negative patients newly diagnosed each year in the United States, EU5, and Japan | “~50K” |
| Of those, patients in the United States | “~18K” |

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-2.2.2.2-7"></a>

### Share of recurrent or metastatic disease that is HPV-negative

> “An estimated 80% of cases of R/M HNSCC are HPV-negative, with testing for HPV status typically only being conducted in tumors originating from the oropharynx.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.2.2.2-8"></a>

### Positioning relative to pembrolizumab-based standard of care

> “In total, ficerafusp alfa 1500mg QW in combination with pembrolizumab has demonstrated a two-to-three-fold increase in median OS as compared to both pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy, which in total represent current standard of care for HPV-negative HNSCC patients.”
> “No head-to-head studies have been conducted, and cross-trial comparisons may not be reliable due to differences in molecule composition, trial design, and patient population and characteristics.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.2.2.2-9"></a>

### Proposed chemotherapy-free first-line regimen

> “Overall, these results suggest that ficerafusp alfa plus pembrolizumab could provide a chemotherapy-free regimen for patients with R/M HNSCC, including those with symptomatic locoregional disease in whom a rapid and durable treatment response would be beneficial.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.2-10"></a>

### Company statement on market entry

> “aiming for ficerafusp alfa to enter the market with a competitive profile that gives physicians, patients, and payers a clear reason to choose it.”

Source: [Bicara Therapeutics third quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2026-financial-results)

<a id="topic-2.2.2.2-11"></a>

### Weekly intravenous administration with pembrolizumab every 3 weeks

> “Eligible patients received pembrolizumab 200 mg intravenously (IV) on day 1 and ficerafusp alfa 1,500 mg IV on days 1, 8, and 15 in 21-day cycles until disease progression, death, unacceptable toxicity, loss to follow-up, or withdrawal of consent.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.2-12"></a>

### Infusion duration and post-infusion observation in the phase 1b protocol

> “Pembrolizumab will be administered using a 30-minute IV infusion.”
> “BCA101 will be administered once a week (or once every other week, according to the assigned cohort) via IV infusion over 120 minutes. BCA101 infusions can be extended to up to 4 hours if clinically indicated.”
> “Subjects should be closely observed and vital signs should be monitored for 2 hours after their first 2 doses of combination therapy”

Source: [Bicara Therapeutics clinical trial protocol BCA101X1101 (2024)](https://ascopubs.org/doi/suppl/10.1200/JCO-25-02027/suppl_file/protocol_JCO-25-02027.pdf)

<a id="topic-2.2.2.2-13"></a>

### Less frequent dosing under evaluation for patients and providers

> “which supported our plans to develop an alternate dosing regimen to expand optionality for patients and providers.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

> “Enhance convenience and patient flexibility by offering less-frequent dosing option in combination with pembrolizumab”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="topic-2.2.2.2-14"></a>

### Practice setting of first-line pembrolizumab in U.S. real-world data

| Practice type of individuals receiving first-line pembrolizumab | All, n (%) | Monotherapy, n (%) | With chemotherapy, n (%) |
| --- | --- | --- | --- |
| Community | “583 (90.2)” | “384 (89.1)” | “199 (92.6)” |
| Academic | “57 (8.8)” | “43 (10.0)” | “14 (6.5)” |

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
